

MILLY CHETAN LALSETA

Address: Flat No. A 801, Vasant Kunj, Near Pradyuman Villa, Opp. Neel Da
Dhaba, Phushkardham Main Road, Rajkot -- 360005

To,

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001

Dear Sir,

Sub.: Disclosure under Regulation 29 of SEBI Regulation, 2011 (Substantial Acquisition of Shares and Takeover)

Ref.: Name- APTUS PHARMA LIMITED (INE15XJ01010) – CODE - APPL

With reference to the subject matter, enclosed herewith please find the details of Shares Purchase of Aptus Pharma Limited in term of Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeover) Regulation, 2011 on 11.05.2026

Kindly take the same on your records and acknowledge the receipt.



Milly Chetan Lalseta

Date: 13.05.2026

Place: Rajkot

Disclosures under Regulation 29(1) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Date: 13.05.2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001

Aptus Pharma Limited
Attn: The Compliance Officer

Sub: Disclosure under Regulation 29(1) / 29(2) of the SEBI (SAST) Regulations, 2011 — Acquisition of equity shares of Aptus Pharma Limited (Scrip Code: 544529; ISIN: INE15XJ01010)

Part-A- Details of the Acquisition

Name of the Target Company (TC)	Aptus Pharma Limited		
Name(s) of the acquirer/Seller and Persons Acting in Concert (PAC) with the acquirer/Seller	Ms. Milly Chetan Lalseta (Promotor / Promotor Group)		
Whether the acquirer/ Seller belongs to Promoter/Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited (SME)		
Details of the acquisition/ disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition/disposal under consideration, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	5,75,000	8.38%	0
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/others)			
c) Voting rights (VR) otherwise than by equity shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding			

in each category) e) Total (a+b+c+d)	5,75,000	8.38%	0
Details of acquisition/-sale			
a) Shares carrying voting rights acquired b) VRs acquired otherwise than by equity shares c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying category) acquired d) Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others) e) Total (a+b+c+d+/-d)	18,000 18,000	0.26% 0.26%	0 0
After the acquisition, Sale, holding of along with PACs of:			
a) Shares carrying voting rights b) VRs otherwise than by equity shares c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition d) Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others) e) Total (a+b+c+d)	5,93,000 5,93,000	8.64% 8.64%	0 0
Mode of acquisition / Sale (e.g. open market / public issue / rights issue / preferential allotment / inter-set transfer / encumbrance, etc.)	Off-market inter-se transfer among Promoter Group		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	NA		
Date of acquisition of / Sale of Shares / date of receipt of intimation of allotment of shares / VR / warrants / convertible securities / any other instrument that entitles the acquirer to receive shares in the TC.	11.05.2026		
Equity share capital / total voting capital of the TC before the said acquisition	68,60,000 equity shares of Rs. 10/-		
Equity share capital / total voting capital of the TC after the said acquisition	68,60,000 equity shares of Rs. 10/-		

Total diluted share/voting capital of the TC
after the said acquisition

68,60,000 equity shares of Rs. 10/-

Part-B***

Name of the Target Company: Aptus Pharma Limited (ISIN: INF15X101010)



Milly Chetan Lalseta

Place: Rajkot